Alliance Medical is established as a leading provider of molecular imaging services through its European network of 12 radiopharmacy facilities and over 50 PET-CT imaging facilities, providing PET-CT imaging to over 150,000 patient each year.
Under the agreement, Alliance Medical will expand its capacity in Spain and Portugal, with the addition of six PET-CT imaging centres, one radiopharmacy, two radiotherapy centres and a radiotherapy support and consultancy business.
In addition to introducing immediate scale into Alliance Medical’s Iberian operations, the combination of Alliance Medical’s market presence and reputation with Mercurius Iberia’s existing commercial pipeline will serve to further support world class nuclear medicine services in the region.
The acquisition will also introduce radiotherapy services into Alliance Medical’s existing suite of nuclear medicine capability, supporting further diversification across all its regions. Access to Mercurius’ established radiotherapy provenance creates an opportunity for Alliance Medical to expand its focus on the oncology pathway, providing further benefits to clinicians and patients throughout Europe.
Nick Burley, Alliance Medical Group Chief Executive Officer said,
“Alliance Medical has been incredibly successful at building Europe’s leading integrated molecular imaging service, increasing radiopharmacy production and PET-CT imaging services in all our regions. The acquisition of Mercurius Iberia not only expands our presence in that region, it also further demonstrates our ambition to bring even greater value to the nuclear medicine field through an expansion into radiotherapy treatment services. Together with all my Alliance Medical colleagues, I am delighted to welcome the Mercurius team into the Alliance Medical family”.
Antonio Sotto Mayor, Alliance Medical Iberia Managing Director said,
“We are proud to bring Mercurius Health’s deep expertise in radiotherapy into the Alliance Medical Group, contributing proven clinical excellence and best practices to a wider European platform. At the same time, being part of Alliance Medical allows us to learn from its robust molecular imaging infrastructure, operational scale, and innovation-driven culture—creating a powerful synergy that will elevate patient care and accelerate our impact across the oncology pathway.”
Alliance Medical (www.alliancemedical.com) is a market leading provider of complex diagnostic imaging, molecular imaging and radiopharmacy production services. Its core markets are the UK, Ireland, Italy, Iberia, Germany and Saudi Arabia.
Mercurius Health is an Iberian leader of clinical services to public and private hospitals and oncology centres with specialisations in radiotherapy, nuclear medicine and radiology.
